Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

This study has been completed.

Study NCT00334438 Information provided by UNC Lineberger Comprehensive Cancer Center

First Received: June 6, 2006 Last Updated: January 9, 2012 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	October 2011
Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)